arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Axsome Therapeutics, Inc.

AXSM
$203.00 ▼ -2.28 (-1.11%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
48 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
15
Health
Poor
Bearish
auto_awesome

Analytical Summary

Axsome Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $10.5B
Dividend Yield
Revenue Growth 45.5%
Op. Margin -22.7%
ROIC -24.7%
FCF / Share $-0.64
Trailing P/E
Price / Book 127.5x
FCF Yield
Debt / Equity 1.42
info Valuation on last close. End-of-day price, Sep 22, 2026.

48-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$218.38M
↑ +45.5%
Net Income Profit after all expenses
$-64.54M
↓ -8.6%
Operating Margin Operating profit as % of sales
-22.7%
↑ +31.4% 9th
FCF / Share Free cash flow per share
$-0.64
↓ -58.6%
Long-Term Debt Long-term obligations
$117.96M
— +0.1%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
9
Returns
2
Financial Health
25
Cash Quality
41

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 13 years · 48 quarters